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INTRODUCTION
Acute pancreatitis (AP) is an inflammatory condition of the 
pancreas in which adjacent tissues and remote organ sys-
tems may also be involved. The chief symptom is abdomi-
nal pain that is usually associated with severe nausea and 
vomiting lasting for several days. Severe abdominal pain 
is mostly reported in the epigastric region or right upper 
quadrant and in some patients, radiates to the back. It is 
particularly difficult to establish a diagnosis in the elderly 
(1-3). The entity generally causes severe and persistent 
pain, and thus, necessitates effective treatment (4).
Effective treatment of pain is warranted in the manage-
ment and this does not hamper diagnosis or treatment. 
An agreement has not yet been reached as to which 
analgesics are useful in treating pain in patients with AP 
(4). Opioids are considered an appropriate choice in this 
context. These drugs are known to decrease the need 
for supplementary analgesia. Opioids are commonly 
used to manage pain in patients with AP, although 
there are some unclear points with regard to their clini-
cal effectiveness and safety (1,4). In contrast, intrave-
nous paracetamol is a cyclooxygenase inhibitor that 
has been documented to have comparable effective-
ness with opioids in the last decades in an emergency 
setting and in various acute pain patterns (5,6).
In this study, the analgesic effectiveness of tramadol, a 
synthetic opioid, was compared with paracetamol and 
dexketoprofen in adult patients with AP in an emergen-
cy department (ED). 
MATERIALS AND METHODS
Study setting and design
This prospective, randomized, controlled study was 
conducted in ED of a tertiary care hospital with an an-
nual census of 324,000 adult patients between January 
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ABSTRACT
Background/Aims: In this study, the analgesic effectiveness of tramadol, a synthetic opioid, was compared 
with paracetamol and dexketoprofen in adult patients with acute pancreatitis in the emergency department. 
Materials and Methods: Study drugs were similar in color and appearance, enabling the patients to be blind 
to the intervention. Study patients were intravenously administered 1 g paracetamol, 50 mg dexketoprofen 
trometamol, or 1 mg/kg tramadol with 100 mL normal saline with a 4-5 min infusion. Pain measurements of the 
patients were conducted at baseline and 30 min after the treatment intervention. Changes in pain scores were 
calculated by subtracting the median scores at baseline and 30 min as pairs. 
Results: In this study, 90 patients were enrolled and included in the final analysis. The study subjects had a 
mean age of 53.5±13.3 years and 58.9% (n=53) of them were male. Gallstones and biliary etiology for pancre-
atitis was documented in 73.3% (n=66) of patients. Mean VAS scores at baseline and 30 min were similar in 
the three groups. Similarly, the change of scores from the baseline to the 30th minute did not differ among the 
groups. Comparison of pain improvements failed to reveal any differences among groups.
Conclusion: Intravenous paracetamol, dexketoprofen, and tramadol are not superior to each other in the man-
agement of pain caused by nontraumatic acute pancreatitis.  
Keywords: Acute pancreatitis, treatment, pain, paracetamol, tramadol
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and June 2014. The local institutional review board approved 
the study. The study was planned as a superior trial with three 
interventions arm: intravenous paracetamol, dexketoprofen, 
and tramadol.
Selection of participants
The study enrolled all consecutive adult patients who were re-
ferred to ED with acute abdominal pain and were diagnosed with 
AP after laboratory examination and computed tomography re-
sults had been obtained. All patients underwent standard diag-
nostic and therapeutic procedures that were predetermined in 
the study protocol. Exclusion criteria were as follows: 
• Those with symptoms for >24 h. 
• VAS values <40/100 mm 
• Ongoing treatment with NSAID (has taken the drug with-
in 24 h) 
• Comorbidities such as diabetes mellitus, congestive 
heart failure, chronic liver failure/cirrhosis, and chronic 
renal failure 
• Those with a history of allergy to paracetamol, dexketo-
profen, and/or tramadol
• Those with a history of trauma 
• Those who declined to participate in the study 
Interventions 
Al patients were randomized in a 1:1:1 ratio. Random number 
table was used to allocate patients to either of the three treat-
ment arms. Computerized six randomization blocks were pre-
pared and scheduled by a person blinded to the study. Treat-
ment allocation assignments and numbers were contained 
in sealed envelopes. Study drugs were identical in color and 
appearance, enabling the patients’ blindness to the interven-
tion. Study patients were intravenously administered 1000 mg 
paracetamol (Parol, Atabay, İstanbul, Turkey), 50 mg dexketo-
profen trometamol (Arveles, IE Ulagay-Menarini; İstanbul, Tur-
key), or 1 mg/kg tramadol (Contramal, Abdi İbrahim, Istanbul, 
Turkey) in 100 mL normal saline with a 4-5 min infusion. Patients 
were blinded to the study; thus, the study was conducted in a 
single-blinded manner. Patients with inadequate pain relief at 
30 min were administered morphine sulfate as a rescue drug.
Methods of measurement
A 100 mm visual analog scale (VAS) displaying numbers be-
tween 0 and 100 (0 mm, no pain and 100 mm, worst pain) was 
used to measure pain intensity. Pain measurements of the pa-
tients were conducted at baseline (just before administering 
the drug) and 30 min after the treatment intervention. Patients 
were blinded to previous VAS scores. Patients were also asked 
if they required any additional drug at the end of the study. 
Adverse effects, such as allergic reaction, nausea and vomiting, 
dyspepsia, and others reported by study subjects, were also re-
corded in the study form. 
Outcome measures
The primary outcome measure was pain relief at 30 min after 
administering the drug. The secondary outcome measures 
were the requirement for a rescue drug and adverse effects 
secondary to study drugs. 
Statistical analysis
Study data were analyzed with SPSS, MedCalc, and Confi-
dence Interval Analysis Software (SPSS Inc.; Chicago, IL, USA). 
Numerical variables were presented as median (interquartile 
range) and frequent variables as rates. Normality analysis was 
performed using the Kolmogorov–Smirnov Test. Three-group 
comparison was conducted using Kruskal–Wallis test. The 
study data were also presented with respect to confidence in-
tervals. All the hypotheses were constructed as two tailed, and 
the alpha critical value was accepted as 0.05. 
RESULTS
Of the 116 patients diagnosed with AP, 26 were excluded from 
the study because of different reasons. Ninety patients (30 
in paracetamol group, 30 in dexketoprofen group, and 30 in 
tramadol group) were enrolled and were included in the final 
analysis (Figure 1). 
The subjects had a mean age of 53.5±13.3 years and 58.9% 
(n=53) were male. Furthermore, 73.3% (n=66) of patients had 
documented gallstones and biliary etiology for pancreatitis. 
The demographical and clinical characteristics of subjects are 
listed in Table 1. 
The subjects were divided into the following three groups: 
paracetamol, dexketoprofen, and tramadol groups. Mean VAS 
scores of the three groups at baseline and 30 min were similar. 
Similarly, the changes in pain scores from baseline to 30 min 
did not differ among the groups (Table 2). 
The changes in pain scores were calculated by subtracting 
the median scores at baseline and 30 min as pairs. According 
to the comparison of pain improvements, there were no dif-
ferences among the groups (dexketoprofen vs. paracetamol, 
paracetamol vs. tramadol, and dexketoprofen vs. tramadol) 
(Table 3). In addition, the trends of scores between baseline 
and 30 min are shown for each group in Figure 2.
Six (20%) patients in the dexketoprofen group, four (13.3%) in 
the paracetamol group, and three (10%) in the tramadol group 
required the administration of a rescue drug. Nausea and 
vomiting were reported by two patients in the dexketoprofen 
group and by one in the paracetamol group. Furthermore, two 
patients had nausea and vomiting and one had a short hypo-
tensive episode in the tramadol group. 
DISCUSSION
Although not very common in ED, AP almost always necessi-
tates pain treatment. The choice of analgesic is currently not 
straightforward. This study compared tramadol, which is an 
opioid that is being more extensively and increasingly (year by 
year) used in treating severe pain in an acute setting, with two 
different cyclooxygenase inhibitors with discrete mechanisms 
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of action. Findings suggested that there is no significant dif-
ference among the treatment arms with regard to analgesic 
efficacy and the requirement for rescue medication. 
Opioids are commonly used in the management of pain caused 
by AP in ED. These drugs were somewhat avoided because 
of the fear that they may mask the manifestation and clinical 
course of the disease, which is currently known to be obso-
lete because many well-designed studies have demonstrated 
that they are safe and effective measures in pain treatment. 
Widespread use of computed tomography also rendered the 
clinical decision-making very effective and expedient, thereby 
enabling judicious use of analgesics.
Opioids were also claimed to increase pain because of their 
spasmogenic effect, which may in turn increase intraluminal 
pressure in the sphincter of Oddi. However, no clear evidence 
is obtained from controlled clinical trials that would support 
this theory (1,7). There is no finding in the literature indicating 
the superiority of one specific opioid drug to another in pain 
treatment of patients with AP. Tramadol, an atypical opioid, is a 
narcotic analgesic and has scarce data in the literature regard-
ing its clinical use. 
It works through a combined mechanism of weak l~-receptor 
binding (opioid activity) and the inhibition of serotonin and 
norepinephrine uptake (nonopioid activity). This dual mecha-
nism of action is considered to underlie its effectiveness in 
some pain patterns that are poorly responsive to conventional 
opioids. Tramadol is associated with some adverse events, such 
as nausea and vomiting (most common), dizziness, headache, 
hypotension, seizures, and respiratory depression (8). Nausea 
Figure 1. Patient flow chart.
Assessed for Eligibility
(n=116)
Excluded:
Failure to meet inclusion criteria (n=26)
- Those with VAS score <40 mm (14)
- Those who took NSAID within 2 hrs (6)
- Diabetes mellitus, congestive heart fail-
ure, chronic liver failure/cirrhosis, chronic 
renal failure (4)
- Symptoms for longer than 24 hours (2)
Randomized (n=90)
Lost to follow-up
(n=0)
Lost to follow-up
(n=0)
Analysed (n=30) Analysed (n=30) Analysed (n=30)
Lost to follow-up
(n=0)
Allocated to paracetamol
group (n=30)
Received paracetamol
(n=30)
Allocated to dexketoprofen
group (n=30)
Received dexketoprofen
(n=30)
Allocated to tramadole
group (n=30)
Received tramadole
(n=30)
Allocation
Follow-up Follow-up
Analysis Analysis
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and vomiting were the most common side effects that were 
reported in all groups, although it is difficult to claim that these 
were caused by the drugs themselves as these complaints are 
usually associated with AP. 
Intravenous paracetamol is a drug extensively used and re-
searched in the ED to treat almost all kinds of pain patterns, 
including colicky pain caused by hollow viscera and musculo-
skeletal pain, and was proven to be effective in an acute setting 
(5,9,10). Moreover, this study also supports that paracetamol 
induces efficient analgesia in patients with AP. It should also 
be noted that a high-dose paracetamol has been accused in 
triggering drug-induced AP in the literature (11,12). 
Dexketoprofen trometamol is an outstanding NSAID as it has 
high potency and has a rapid absorption rate, short time to 
peak blood levels, and earlier onset of analgesic efficacy in 
acute pain treatment. Studies have demonstrated that dexke-
toprofen reduces pain by decreasing the consumption of res-
cue opioid administration, and thus, opioid-related side effects 
after various operations (13). This study failed to demonstrate 
its superiority over tramadol with respect to efficacy. Recently, 
some reports have been demonstrated that the combination 
of dexketoprofen and tramadol was used in treating acute pain 
patterns with more remarkable results (14).
Limitations
A number of factors prohibited a double-blind design in this 
study. In addition, study subjects had many different AP etiolo-
gies, which may also have had an impact on different pain re-
sponses to the interventions. Broader well-designed studies may 
minimize such difficulties in pain management research in AP. 
In conclusion, intravenous paracetamol, dexketoprofen, and 
tramadol are not superior to each other in the management of 
pain caused by nontraumatic AP. 
Ethics Committee Approval: Ethics committee approval was received for 
this study from the ethics committee of Bezmialem Vakıf University (2015).
Informed Consent: Written informed consent was obtained from pa-
tients who participated in this study.
Peer-review: Externally peer-reviewed.
Mean Age- Year +-SD 53.5±13.3
Male sex - (n, %) 53 (58.9)
Clinical symptoms and signs - (n, %)
• Abdominal pain 79 (87.7)
• Nausea 39 (43.3)
• Vomiting 11 (12.2)
• Abdominal tenderness 84 (93.3)
• Guarding 23 (25.5)
• Muscular rigidity 12 (13.3)
Etiology for pancreatitis - (n, %)
• Gallstones and biliary pancreatitis 66 (73.3)
• Alcoholic pancreatitis 19 (21.1)
• Others 5 (5.6)
*Each symptom and sign were noted independently.
Table 1. Baseline Characteristic of 90 Patients
 Paracetamol Dexketoprofen Tramadol 
Variable Group Group Group
Visual Analogue Scale
Median with IQR
Baseline 66 (58-80) 58 (51-68) 64.5 (56-74) 
     30th minutes 21 (10-41) 20 (11-32) 20.5 (11-37)
Change from Baseline (VAS)
Median differences with  
95% CI 
     30th minutes 41.5 (34 to 50) 40.5 (30 to 47) 45.5 (30 to 54)
VAS: visual analogue scale; CI: confidence interval; IQR: interquartile range
Table 2. Change in pain intensity at baseline and 30th minutes for each 
study arm
Variable Dexketoprofen vs Paracetamol vs Dexketoprofen vs 
 Paracetamol Tramadol Tramadol 
 Median (95% CI) Median (95% CI) Median (95% CI)
Differences from  
baseline to 30th  3 (-3 to 10) 2 (-7 to 10) 5 (-3 to 13) 
minutes* 
CI: confidence interval
*Three-group comparison revealed a p value of 0.38, so post-hoc analysis was not performed. 
There is also no difference between groups that can be concluded by the confidence 
intervals. 
Table 3. Comparison of pain score changes between two groups.
Figure 2. Temporal trends of VAS scores regarding treatment arms.
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